Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Has Average Price Target of $35.50 According to Brokerages

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have been given an average recommendation of “Hold” by the eight research firms that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $35.50.

Several equities analysts have weighed in on LKFT shares. Weiss Ratings raised Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, October 2nd. UBS Group upgraded Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a research report on Wednesday, September 23rd. Royal Bank Of Canada raised Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $26.00 to $45.00 in a research note on Wednesday, September 23rd. Morgan Stanley initiated coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, October 20th. They issued an “equal weight” rating and a $26.00 price target on the stock. Finally, TD Cowen assumed coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, August 21st. They set a “buy” rating on the stock.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

A number of hedge funds and other institutional investors have recently made changes to their positions in LKFT. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the 1st quarter valued at $248,000. ABC Arbitrage SA bought a new position in Lakefront Biotherapeutics American Depositary Shares during the first quarter worth about $382,000. Finally, QRG Capital Management Inc. lifted its holdings in Lakefront Biotherapeutics American Depositary Shares by 21.9% during the first quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock worth $591,000 after acquiring an additional 3,535 shares in the last quarter. 32.46% of the stock is owned by institutional investors.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

Shares of LKFT opened at $31.82 on Friday. Lakefront Biotherapeutics American Depositary Shares has a 12 month low of $25.68 and a 12 month high of $36.24. The company has a 50-day moving average price of $29.27 and a two-hundred day moving average price of $29.98.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its quarterly earnings data on Monday, August 10th. The biotechnology company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.97) by $1.00. The firm had revenue of $15.47 million for the quarter, compared to the consensus estimate of $7.29 million. Analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -1.26 EPS for the current fiscal year.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.